CASI Pharmaceuticals Appoints David Cory as CEO to Drive CID-103 Program

CASI Pharmaceuticals ( (CASI) ) has issued an announcement.

On July 21, 2025, CASI Pharmaceuticals announced the appointment of David Cory as the new Chief Executive Officer, succeeding Wei-Wu He, who will remain as Executive Chairman. David Cory, with over 30 years of experience in biotech and large pharma companies, is expected to enhance CASI’s U.S. operations and focus on advancing the CID-103 program, a promising anti-CD38 monoclonal antibody for autoimmune diseases and organ transplant rejection. This strategic leadership change aims to strengthen CASI’s market position and deliver long-term value to patients and shareholders.

The most recent analyst rating on (CASI) stock is a Buy with a $4.00 price target. To see the full list of analyst forecasts on CASI Pharmaceuticals stock, see the CASI Stock Forecast page.

Spark’s Take on CASI Stock

According to Spark, TipRanks’ AI Analyst, CASI is a Underperform.

CASI Pharmaceuticals is facing severe financial difficulties, reflected in declining revenues and increasing losses, which significantly impact its stock score. Technical analysis supports a bearish outlook, and the lack of profitability is highlighted by a negative P/E ratio. These factors contribute to a weak overall stock score.

To see Spark’s full report on CASI stock, click here.

More about CASI Pharmaceuticals

CASI Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapeutics and pharmaceutical products in China, the U.S., and globally. The company specializes in hematology oncology therapeutics and treatments for organ transplant rejection and autoimmune diseases, leveraging its regulatory and commercial competencies in China and global drug development expertise.

Average Trading Volume: 109,085

Technical Sentiment Signal: Sell

Current Market Cap: $19.52M

See more data about CASI stock on TipRanks’ Stock Analysis page.